Related Experiment Video
Updated: Jun 13, 2026
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition
Branka Radic-Sarikas1,2, Marica Markovic3,4, Martha Magdalena Zylka1
1St. Anna Children's Cancer Research Institute (CCRI), 1090 Vienna, Austria.
Abstract:
Bone sarcomas are rare and aggressive pediatric cancers with limited progress in targeted therapy development, partly due to the poor physiological relevance of conventional two-dimensional (2D) culture systems used for preclinical testing. To address this gap, we developed a standardized three-dimensional (3D) culture and drug-testing platform for Ewing sarcoma (ES) and osteosarcoma (OS) that more accurately recapitulates in vivo tumor biology. Notably, gene-expression analyses demonstrated that ES and OS spheroids transcriptionally converge toward patient tumor cell states, underscoring their physiological relevance for preclinical testing. Across 3D spheroids, bioprinted constructs, and patient-derived xenograft (PDX) cultures, we observed a consistent activation and dependency on the mevalonate pathway in ES. Leveraging this platform, we identified a selective therapeutic synergy between statins, which inhibit mevalonate pathway flux, and BCL-xL inhibitors-a vulnerability not detectable in 2D cultures. Importantly, this synergistic interaction was tumor-specific and absent in non-malignant fibroblasts, indicating a favorable therapeutic window. Together, these findings highlight the mevalonate pathway as a targetable metabolic dependency in ES and demonstrate how physiologically grounded 3D models can uncover clinically actionable treatment strategies that remain hidden in traditional 2D systems.
Insights
New 3D models for pediatric bone cancers like Ewing sarcoma (ES) and osteosarcoma (OS) reveal a metabolic vulnerability. This approach identified a synergistic therapy targeting the mevalonate pathway, improving preclinical drug testing.
Area of Science:
- Oncology
- Biotechnology
- Cancer Biology
Background:
- Pediatric bone sarcomas (Ewing sarcoma and osteosarcoma) are aggressive cancers with limited targeted therapy progress.
- Conventional 2D cell cultures lack physiological relevance for preclinical cancer drug testing.
Purpose of the Study:
- To develop and validate a 3D culture and drug-testing platform for pediatric bone sarcomas.
- To identify novel therapeutic targets and strategies for Ewing sarcoma (ES) and osteosarcoma (OS) using advanced models.
Main Methods:
- Standardized 3D culture platform development for ES and OS.
- Gene-expression analysis of 3D spheroids compared to patient tumors.
- Drug screening using 3D spheroids, bioprinted constructs, and patient-derived xenografts (PDX).
Main Results:
- 3D ES and OS models demonstrated transcriptional convergence with patient tumor cells, confirming physiological relevance.
- A consistent activation and dependency on the mevalonate pathway was observed in ES across different 3D models.
- A synergistic therapeutic effect was identified between statins and BCL-xL inhibitors, specifically targeting the mevalonate pathway in ES.
Conclusions:
- The mevalonate pathway represents a targetable metabolic vulnerability in Ewing sarcoma.
- Physiologically relevant 3D models are crucial for uncovering clinically actionable treatment strategies missed by 2D cultures.
- The identified statin and BCL-xL inhibitor synergy offers a promising, tumor-specific therapeutic window for ES treatment.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle